Rare Pediatric Disease Voucher Program Gains Temporary Extension From House Committee
Executive Summary
US incentive program would gain only four more years, despite calls for a permanent extension.
You may also be interested in...
Priority Review Voucher Fee Decreases For FY 2021 May Reflect US FDA Personnel Changes
In part because assessment costs plummeted in FY 2019, the FY 2021 fee to redeem a priority review voucher will be 37% less than the previous year.
Rare Pediatric Disease Designation Requests Skyrocket Ahead Of Voucher Program’s Sunset
US FDA received 110 designation requests in July, a high mark that reflects the 60 days needed to review such requests ahead of the 30 September statutory expiration; agency is allowing email submission of RPD and orphan drug designation requests during the COVID-19 pandemic and expects to roll out an online portal for orphan designation requests later this year.
Rare Genetic Epilepsy Responsive To Marinus's Ganaxolone
Marinus Pharmaceuticals has transformed its finances and the prospects for its R&D pipeline over the past 12 months, and has just reported positive top-line results from the Phase III MARIGOLD study of its lead compound, ganaxolone.